Sofinnova Crossover I SLP converted into ordinary shares of the Company all of the 7,500,000 convertible bonds (“CBs”) it had subscribed for in June 2019
- Sofinnova Crossover I SLP converted into ordinary shares of the Company all of the 7,500,000 convertible bonds (“CBs”) it had subscribed for in June 2019
- The conversion was undertaken on a price basis of €0.76 per share
- Sofinnova Crossover I SLP now holds 11,822,258 ordinary shares and 20.19% of the share capital and voting rights of Sensorion
MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:
Sensorion (FR0012596468 – ALSEN / PEA-PME eligible) (Paris:ALSEN), a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces Sofinnova Crossover I SLP converted into ordinary shares all the convertible bonds it had subscribed for in June 2019.
Sofinnova Crossover I SLP converted into ordinary shares of the Company all of the 7,500,000 convertible bonds (“CBs”) it had subscribed for in June 2019. The conversion of these CBs has been undertaken in accordance with the terms of the CBs on the basis of a reference price corresponding to the lower of (a) €1.3662, and (b) the volume weighted average of the prices of the trading sessions during a three-month period ending on the trading day preceding the conversion request date, i.e. €0.76. The number of ordinary shares issued by the Company as a result of such conversion is 9,868,421 and these new ordinary shares will be listed on Euronext Growth on the same trading line as the existing ordinary shares (ISIN Code FR0012596468). Following the conversion of the CBs, Sofinnova Crossover I SLP holds 11,822,258 ordinary shares of the Company, representing 20.19% of the share capital and voting rights of the Company.
New capital structure
| Before conversion of | After conversion of | On a fully diluted basis | |||||
| Number of | Capital | Number of | Capital | Number of | Capital | ||
| Inserm Transfert Initiative | 982,911 | 2.02% | 982,911 | 1.68% | 982,911 | 1.61% | |
| Innobio (Bpifrance) | 3,499,874 | 7.19% | 3,499,874 | 5.98% | 3,499,874 | 5.74% | |
| Management, employees, directors(1)(3)(4) | 221,582 | 0.46% | 221,582 | 0.38% | 1,817,493 | 2.98% | |
| Cochlear | 533,755 | 1.10% | 533,755 | 0.91% | 533,755 | 0.88% | |
| Invus | 20,591,259 | 42.29% | 20,591,259 | 35.16% | 20,591,259 | 33.80% | |
| Sofinnova Partners (OC 0624)(2) | 1,953,837 | 4.01% | 11,822,258 | 20.19% | 11,822,258 | 19.40% | |
| New Investors (september 2019 capital raise) | 9,489,051 | 19.49% | 9,489,051 | 16.20% | 9,489,051 | 15.57% | |
| Free Float (including former officers)(4) | 11,422,362 | 23.46% | 11,422,362 | 19.50% | 12,192,741 | 20.01% | |
| Total | 48,694,631 | 100.00% | 58,563,052 | 100.00% | 60,929,342 | 100.0% | |
| Assumptions before conversion of Sofinnova Partners convertible bonds: | |||||||
About Sensorion
Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) for sudden sensorineural hearing loss (SSNHL). Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases enabling it to select the best targets and modalities for drug candidates. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. Sensorion has launched in the second half of 2019 two preclinical gene therapy programs aiming at correcting hereditary monogenic forms of deafness including Usher Type 1 and deafness caused by a mutation of the gene encoding for Otoferlin. The Company is uniquely placed through its platforms and pipeline of potential therapeutics to make a lasting positive impact on hundreds of thousands of people with inner ear related disorders; a significant global unmet medical need.
www.sensorion-pharma.com
Label : SENSORION
ISIN : FR0012596468
Mnemonic : ALSEN
Disclaimer
This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the ‘Document de référence’ registration document filed with the ‘Autorité des Marchés Financiers’ (AMF French Financial Market Authority) on September 7th, 2017 under n°R.17-062 and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200212005690/en/
Contacts
Financial Advisor
Catherine Leveau
catherine.leveau@sensorion-pharma.com
+33 467 207 730
Financial communication
LifeSci Advisors – Sophie Baumont
sophie@lifesciadvisors.com
+33 6 27 74 74 49
Source: Sensorion
View this news release online at:
http://www.businesswire.com/news/home/20200212005690/en
